Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BSX Stock Forecast 2026-2027
$44.81
Current Price
$66.60B
Market Cap
Buy 27
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to BSX Price Targets
+136.6%
To High Target of $106.00
+58.4%
To Median Target of $71.00
+22.7%
To Low Target of $55.00
BSX Price Momentum
-0.7%
1 Week Change
-8.5%
1 Month Change
-56.5%
1 Year Change
-53.0%
Year-to-Date Change
-59.1%
From 52W High of $109.50
+6.1%
From 52W Low of $42.25
📊 TOP ANALYST CALLS
Did BSX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Boston Scientific is one of their latest high-conviction picks.
Latest BSX Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, BSX has a bullish consensus with a median price target of $71.00 (ranging from $55.00 to $106.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $44.81, the median forecast implies a 58.4% upside. This outlook is supported by 27 Buy, 4 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BSX Analyst Ratings
27
Buy
4
Hold
0
Sell
BSX Price Target Range
Low
$55.00
Average
$71.00
High
$106.00
Current: $44.81
Latest BSX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BSX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 8, 2026 | Needham | Buy | Maintains | $N/A | |
| Jul 6, 2026 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| Jun 25, 2026 | Stifel | Buy | Maintains | $N/A | |
| Jun 24, 2026 | Jefferies | Buy | Maintains | $N/A | |
| Jun 16, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Jun 4, 2026 | Truist Securities | Buy | Maintains | $N/A | |
| Jun 3, 2026 | BTIG | Buy | Maintains | $N/A | |
| Jun 1, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| May 29, 2026 | Wolfe Research | Peer Perform | Downgrade | $N/A | |
| May 28, 2026 | Citigroup | Buy | Maintains | $N/A | |
| May 28, 2026 | Leerink Partners | Outperform | Maintains | $N/A | |
| May 28, 2026 | Barclays | Overweight | Maintains | $N/A | |
| May 28, 2026 | Wells Fargo | Equal-Weight | Downgrade | $N/A | |
| May 19, 2026 | Baird | Outperform | Maintains | $N/A | |
| May 18, 2026 | B of A Securities | Buy | Maintains | $N/A | |
| May 18, 2026 | Needham | Buy | Reiterates | $N/A | |
| May 18, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Apr 23, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Apr 23, 2026 | RBC Capital | Outperform | Maintains | $N/A | |
| Apr 23, 2026 | Barclays | Overweight | Maintains | $N/A |
Boston Scientific Corporation (BSX) Competitors
The following stocks are similar to Boston Scientific based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
BSX
Boston Scientific
mkt cap
67.09B
Boston Scientific Corporation (BSX) Financial Data
Boston Scientific Corporation has a market capitalization of $66.60B with a P/E ratio of 18.9x. The company generates $20.61B in trailing twelve-month revenue with a 17.3% profit margin.
Revenue growth is +11.6% quarter-over-quarter, while maintaining an operating margin of +20.6% and return on equity of +14.7%.
Valuation Metrics
Market Cap
$66.60B
Enterprise Value
$76.42B
P/E Ratio
18.9x
PEG Ratio
0.2x
Price/Sales
3.2x
Growth & Margins
Revenue Growth (YoY)
+11.6%
Gross Margin
+69.4%
Operating Margin
+20.6%
Net Margin
+17.3%
EPS Growth
+99.0%
Financial Health
Cash/Price Ratio
+2.2%
Current Ratio
1.9x
Debt/Equity
42.3x
ROE
+14.7%
ROA
+6.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Boston Scientific Corporation (BSX) Business Model
About Boston Scientific Corporation
What They Do
Develops innovative medical devices for procedures.
Business Model
The company generates revenue by designing, manufacturing, and marketing a diverse range of medical devices used in minimally invasive procedures. Its business model focuses on addressing critical health needs in various segments, including cardiology and endoscopy, targeting healthcare professionals and institutions worldwide.
Additional Information
Boston Scientific was founded in 1979 and is headquartered in Marlborough, Massachusetts. It has a strong presence in international markets, significantly contributing to its sales. The company is committed to advancing interventional medicine and enhancing patient outcomes in high-volume therapeutic areas.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
59,000
CEO
Mr. Michael F. Mahoney
Country
United States
IPO Year
1992
Website
www.bostonscientific.comBoston Scientific Corporation (BSX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Boston Scientific (BSX) Stock Dips While Market Gains: Key Facts
Boston Scientific (BSX) closed at $44.6 in the latest trading session, marking a -1.2% move from the prior day.
Jul 06, 2026
By Zacks Equity Research
Tale of the Tape
J&J's MedTech Segment Eyes Another Strong Quarter in Q2
JNJ's Q2 MedTech results will test whether cardiovascular, surgery and vision strength can offset ongoing China VBP headwinds and sustain growth.
Jul 06, 2026
By Kinjel Shah
Analyst Blog
Boston Scientific (BSX) Stock Drops Despite Market Gains: Important Facts to Note
In the most recent trading session, Boston Scientific (BSX) closed at $42.68, indicating a -1.84% shift from the previous trading day.
Jun 30, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Boston Scientific (BSX) closed at $44.60, down 1.2% from the previous trading session.
Why It Matters
Boston Scientific's decline of 1.2% could indicate market concerns about its performance or broader sector trends, potentially affecting investor sentiment and future stock valuation.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Boston Scientific's share price has fallen nearly 60% from its September 2025 high of $109.50, now trading around $45.00. Q1-26 earnings revised growth guidance for 2026 to 6.5%-8.0%.
Why It Matters
Boston Scientific's 60% share price drop and reduced growth guidance signal potential ongoing challenges, impacting investor sentiment and future performance expectations.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Boston Scientific (BSX) closed at $42.68, down 1.84% from the previous trading day in the latest session.
Why It Matters
A 1.84% decline in Boston Scientific's stock price may signal investor concerns or market volatility, potentially affecting future performance and investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Companies face significant investor concern over potential market share losses due to competition from AI tools.
Why It Matters
Concerns over market share loss to AI could signal declining revenues for affected companies, impacting stock performance and investor confidence.
Source: Market Watch
Market Sentiment:
Negative
Quick Summary
Boston Scientific's shares fell 50% due to slowed growth and competition. Management projects 6.5%-8% revenue growth, though long-term growth is expected at 7.5% annually with improving margins.
Why It Matters
Boston Scientific's stock decline reflects growth concerns amid competition and reimbursement issues, yet fundamentals suggest potential for recovery with attractive valuations and expected margin improvements.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Wall Street analysts' recommendations influence investors' decisions and can impact stock prices, raising questions about their significance in the market.
Why It Matters
Wall Street analyst ratings influence stock prices and investor sentiment, impacting trading decisions and market trends. Their recommendations can signal potential stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About BSX Stock
What is Boston Scientific Corporation's (BSX) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, Boston Scientific Corporation (BSX) has a median price target of $71.00. The highest price target is $106.00 and the lowest is $55.00.
Is BSX stock a good investment in 2027?
According to current analyst ratings, BSX has 27 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $44.81. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BSX stock?
Wall Street analysts predict BSX stock could reach $71.00 in the next 12 months. This represents a 58.4% increase from the current price of $44.81. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Boston Scientific Corporation's business model?
The company generates revenue by designing, manufacturing, and marketing a diverse range of medical devices used in minimally invasive procedures. Its business model focuses on addressing critical health needs in various segments, including cardiology and endoscopy, targeting healthcare professionals and institutions worldwide.
What is the highest forecasted price for BSX Boston Scientific Corporation?
The highest price target for BSX is $106.00 from at , which represents a 136.6% increase from the current price of $44.81.
What is the lowest forecasted price for BSX Boston Scientific Corporation?
The lowest price target for BSX is $55.00 from at , which represents a 22.7% increase from the current price of $44.81.
What is the overall BSX consensus from analysts for Boston Scientific Corporation?
The overall analyst consensus for BSX is bullish. Out of 3 Wall Street analysts, 27 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $71.00.
How accurate are BSX stock price projections?
Stock price projections, including those for Boston Scientific Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 9, 2026 4:40 PM UTC